Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • Guaranteed Paid Placement
  • SocialBoost
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • SocialBoost
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Awareness of Heart Disease in Women Remains Low

SLO-NIACIN(R) OFFERS AN AFFORDABLE OPTION FOR CHOLESTEROL MANAGEMENT


News provided by

Upsher-Smith Laboratories, Inc.

Feb 10, 2010, 07:30 ET

Share this article

Share toX

Share this article

Share toX

MAPLE GROVE, Minn., Feb. 10 /PRNewswire/ --Cardiovascular disease (commonly referred to as heart disease) is the leading cause of death for women worldwide. (1) Almost every minute, a woman in the U.S. dies from heart disease. Despite the prevalence of heart disease in women, a 2005 American Heart Association study showed that 92% of primary care physicians and 83% of cardiologists were not aware of the fact that more women than men die of heart disease each year. (1)

"Major initiatives are under way to increase awareness of the fact that more women than men die each year of heart disease, yet awareness remains low," states Mark Evenstad, president of Upsher-Smith Laboratories, Inc.  "At Upsher-Smith, we are committed to women's health so we are working to increase awareness of Slo-Niacin®, a niacin dietary supplement. Niacin is clinically proven to help manage cholesterol, a major factor in heart health."

One of the major factors contributing to heart disease is cholesterol. To be considered healthy, one's total cholesterol number should be less than 200 mg/dL, but the average cholesterol level in an adult American is about 203 mg/dL.(2,3) Beginning at age 45, more women than men have total cholesterol greater than 200 mg/dL. (4)

"Everyone with elevated cholesterol should be aware of their cholesterol management options," states Evenstad. "Slo-Niacin® is a well established and affordable option."

Niacin, or nicotinic acid, is a type of B vitamin that aids in the function of the digestive system, skin, nerves and heart health. The adult body needs at least 14-16 mg of niacin daily to function properly.(5) First used in the 1950s, niacin is the oldest of today's commonly used agents for lowering cholesterol.(6)

Slo-Niacin® is a nonprescription dietary supplement that, when used under the care and monitoring of a healthcare provider, has been clinically proven to raise HDL ("good cholesterol"), and lower LDL ("bad cholesterol"), total cholesterol, and triglycerides on its own and in combination with other cholesterol-lowering agents, such as statins.(7, 10-12)

The SLIM study, published last year in the Journal of Clinical Lipidology, evaluated the effects of Slo-Niacin® and Lipitor® given separately and together. With proper monitoring and dosing, combination therapy was shown to have a greater effect on cholesterol levels than either agent alone. Monotherapy with Slo-Niacin® decreased median triglyceride levels 15%, mean LDL 12% and increased HDL 8%.(7) Persons already taking cholesterol-lowering drugs should contact their healthcare provider before taking niacin because of possible side effects.(8)

Dietary supplement niacin is sold in three forms: immediate-release, controlled-release and "flush-free." Immediate-release niacin can be inconvenient because it requires relatively small doses to be taken several times a day and the side effects, such as flushing, can be problematic. Controlled-release niacin, such as Slo-Niacin®, contains nicotinic acid and is less likely to cause flushing. Inositol hexaniacinate and nicotinamide, both referred to as "flush-free" niacin, prevent flushing but have not been shown to have any effect on cholesterol levels. Only nicotinic acid has been shown to have beneficial effects on cholesterol.(6)

Slo-Niacin® Tablets utilize a patented polygel® controlled-release delivery system, not available in other dietary supplement niacin products, which assures the gradual and measured release of niacin. It is designed to reduce the incidence of flushing commonly associated with niacin use.(8)

As an affordable dietary supplement, Slo-Niacin® is economical and often costs less than an insurance co-payment. At approximately $16 per month for 100 500-mg tablets, Slo-Niacin® helps heart health without hurting your wallet.(9) Patients should talk with their healthcare provider about how Slo-Niacin® may help them.

Three dosage strengths (250 mg, 500 mg, and 750 mg) of Slo-Niacin® Tablets are available to meet the specific goals your set with your healthcare provider. But before using more than 500 mg daily, consult your healthcare provider, because niacin can cause side effects when used in high doses.(8) Proper monitoring by a healthcare provider can help manage side effects.  

Slo-Niacin® Tablets are manufactured by Upsher-Smith Laboratories, Inc., a trusted manufacturer of high quality prescription and dietary supplement products, and are conveniently available at pharmacies and other retailers nationwide. For more information, contact a healthcare professional, call 1-800-654-2299 or visit www.Slo-Niacin.com for more information, coupons and a store locator.

About Upsher-Smith Laboratories, Inc.

Upsher-Smith Laboratories, Inc. is a rapidly growing pharmaceutical company that manufactures and markets both prescription and consumer products. Privately held since 1919, the company strives to recognize the unmet healthcare needs of our customers. Over the last 20 years that Upsher-Smith has been manufacturing Slo-Niacin®, more than 10 million bottles have been sold. Upsher-Smith prides itself in providing safe, effective, and economical therapies to the ever-challenged healthcare environment. For additional information about Upsher-Smith, visit www.upsher-smith.com.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat or prevent any disease.

Important Safety Information

Read the information leaflet provided with each bottle of Slo-Niacin® Tablets.

Do not use Slo-Niacin® Tablets if you have a known sensitivity or allergy to niacin.  Do not take niacin unless under your doctor's supervision if you have heart disease (particularly, recurrent chest pain or recent heart attack), gallbladder disease, gout, arterial bleeding, glaucoma, diabetes, impaired liver function, stomach ulcers, or are pregnant or lactating.  Before taking more than 500 mg/day, call your doctor. If you are taking high blood pressure or cholesterol-lowering drugs, call your doctor before taking niacin due to possible interactions. Case reports of unexplained muscle-related complaints, including discomfort, weakness, or tenderness, have been documented with HMG-CoA Reductase Inhibitors in combination with niacin. Increased uric acid, glucose, and abnormal liver function tests have been reported in persons taking 500 mg/day or more.  Discontinue use and call your doctor immediately if you experience persistent flu-like symptoms (nausea, vomiting, not feeling well), loss of appetite, decreased and dark-colored urine, muscle discomfort or weakness, irregular heartbeat or vision problems.  Niacin may cause temporary flushing, itching and tingling, feelings of warmth and headache, particularly when beginning, increasing dosage or changing brands. This safety information is not all-inclusive. For more information, contact your health care provider, call 1-800-654-2299, or visit www.slo-niacin.com.

104114.01

(1)  Women Heart - The National Coalition for Women with Heart Disease. Myths & Truths on Women & Heart Disease. http://www.womenheart.org/resources/mythstruths.cfm. Accessed January 15, 2010.

(2)  Centers for Disease Control and Prevention. Heart Disease Facts. http://www.cdc.gov/heartDisease/facts.htm, 2010. Page last updated: January 25, 2010.

(3)  American Heart Association. http://www.americanheart.org/presenter.jhtml?identifier=4506. April 13, 2009.

(4)  MedlinePlus. Heart Disease Affects Women of All Ages. http://www.nlm.nih.gov/medlineplus/magazine/issues/winter07/articles/winter07pg6.html. Accessed January 15, 2010.

(5)  MedlinePlus. Niacin. http://www.nlm/nih.gov/medlineplus/ency/article/002409.htm. Accessed December 17, 2009.

(6) Harvard Health Letter. "Niacin into the void: Failure of HDL cholesterol drug may be this B vitamin's big chance." April 2007.

(7) Knopp RF, Retzlaff BM, Fish B et al. "The SLIM study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia." Journal of Clinical Lipidology, Volume 3, Issue 3, Pages 167-178.

(8) Slo-Niacin product information. http://www.slo-niacin.com/images/pi.pdf.

(9) Drugstore.com website. http://www.drugstore.com. Accessed June 23, 2008.

(10) Lavie CJ, Mailander L, Milani. "Marked benefit with sustained-release niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary heart disease." Am J Cardiol. 1992;69:1083-1085.

(11) Squires RW, Allison TG, Gau GT, et al. "Low-Dose, Time-Release Nicotinic Acid: Effects in Selected Patients With Low Concentrations of High-Density Lipoprotein Cholesterol." Mayo Clin Proc. 67:855-860, 1992.

(12) Gray DR, Morgan T, Chretien SD, Kashyap ML. "Efficacy and Safety of Controlled-Release Niacin in Dyslipoproteinemic Veterans." Ann Intern Med. 1994;121:252-258.

Lipitor® is a registered trademark of Pfizer Inc.

SOURCE Upsher-Smith Laboratories, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.